SorafenibTyrosine kinase inhibitor (Oncology) Indication: SorasibaTM is indicated for the treatment of:• Patients with unresectable hepatocellular carcinoma (HCC).• Patients with advanced renal cell carcinoma (RCC).• Patients with Differentiated Thyroid Carcinoma (DTC). Dosage & Administration: The recommended daily dose of SorasibaTM is 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour […]